Real-world use of brexpiprazole during inpatient treatment for schizophrenia: continuation, discontinuation, and concomitant psychotropics - Summary - MDSpire
Advertisement
Real-world use of brexpiprazole during inpatient treatment for schizophrenia: continuation, discontinuation, and concomitant psychotropics
To investigate the real-world use of brexpiprazole among patients hospitalized with acute schizophrenia, focusing on 8-week treatment continuation and reasons for discontinuation, including adverse events and efficacy.
Key Findings:
53.7% of 67 patients continued brexpiprazole to week 8.
Continuation was associated with female sex, lower prior chlorpromazine-equivalent dose, and shorter duration of untreated psychosis.
Adverse events (32.3%) were the most common reason for discontinuation, particularly akathisia.
Interpretation:
Brexpiprazole shows potential for continuation in acute inpatient schizophrenia care, but addressing adverse events and insufficient efficacy is crucial for improving treatment outcomes.
Limitations:
Retrospective single-center design may introduce selection and information bias, potentially affecting the generalizability of the results.
Unmeasured confounding factors may affect results, limiting causal inferences.
Conclusion:
Further studies are warranted to clarify the clinical positioning of brexpiprazole in real-world practice for schizophrenia management.
